Onco-Summaries: Daily Oncology Updates at a Glance

29/07/2026

---

• The US FDA Grants RMAT & Fast Track to Allogene’s Cema‑cel for first‑Line LBCL consolidation

---

The US FDA Grants RMAT & Fast Track to Allogene’s Cema‑cel for first‑Line LBCL consolidation (Ref)

RMAT & Fast Track status granted to cemacabtagene ansegedleucel (cema‑cel; CAR T‑cell therapy) for the treatment of adult patients with large B-cell lymphoma (LBCL) who, at the completion of first-line therapy, are in complete or partial response suitable for observation but test positive for minimal residual disease (MRD)

Designation granted following full review of the interim futility analysis from the ongoing ALPHA3 trial

• Interim futility analysis showed 58.3% MRD clearance in the cema‑cel arm vs 16.7% in the observation arm (absolute difference: 41.6%)

• 97.7% median decrease in plasma ctDNA at Day 45 with cema‑cel, compared to a 26.6% median increase in the observation arm

• Suggests clinically meaningful benefit, as literature benchmarks indicate 25–30% MRD clearance differences can translate into improved outcomes

Return to Top